Global Herpes Market is expected to grow with the CAGR of 6.6% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-herpes-market

Global herpes market is highly consolidated and includes specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenario.    

Major players dealing in the global herpes market are introducing a wide range of products and adopting strategic initiatives, such as acquisitions, agreements, into the market. This has helped companies maximize their sales with enhance their product portfolio.

For instance,

• In September 2018, Avet Pharmaceuticals Inc. announced the immediate availability of Acyclovir 200 mg capsules. This launch enhanced Avet’s broad portfolio of generic oral solid products. This new drug launched by the company has increased its sales in the market, leading to increased revenue in the future.

GlaxoSmithKline plc, is the dominating player in the global herpes market. Other key players existing in the market include Abbott, Apotex, Inc., Avet Pharmaceuticals, Inc., Bausch Health Companies, Inc. Cipla, Inc., Dr. Reddy’s Laboratories Ltd., EPI Health, Fresenius Kabi AG, GlaxoSmithKline plc., Glenmark Pharmaceutical Inc., USA, Maruho Co.,Ltd.,  Mylan N.V.,  Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., RECORDATI S.p.A., Aurobindo Pharma, Amneal Pharmaceuticals LLC, Slavia Pharm S.R.L., and Blistex, Inc. among others.

GlaxoSmithKline plc

GlaxoSmithKline plc was established in 1715, and headquartered in London. The company is engaged in the research development and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It has following business segments including pharmaceuticals, vaccines, and consumer healthcare, in which pharmaceuticals is the market focused segment. The company also provides various product categories including prescription medicines. Vaccines, consumer healthcare products, ViiV healthcare, and Stiefel dermatology in which the market focused products lie under prescription medicines and Vaccines.

For instance,

• In January 2021, GSK ranked 1st in the 2021 Access to Medicine Index with leading R&D pipeline for priority diseases. The ranking is based on progress companies that are making efforts in improving access to medicine in 106 low- and middle-income countries and in relation to 82 diseases, conditions, and pathogens. This will increase the demand for the company’s products in the forecast period.

The company has wide presence in North America, South America, Asia-Pacific, Middle East, and Africa. The company also has subsidiaries companies such as Barrier Therapeutics, Inc (US), GlaxoSmithKline – Produtos Farmaceuticos, Limitada (Portugal), GlaxoSmithKline Biologicals Kft. (Hungary), and GlaxoSmithKline Consumer Holding B.V. (Netherlands) among others.

Viatris Inc.

Viatris Inc. was founded in 1961 and headquartered in Pennsylvania, U.S. The company works in the healthcare domain with the production of drugs including prescription generic, branded generic, brand-name and biosimilar drugs, as well as over-the counter remedies. It offers a variety of products such as therapeutic areas, brands, biosimilar, generics, over-the-counter and API, in which the market focused products lie under generics. The company has initiated many strategic initiatives to expand its market.

For instance,

• In November 2019, Mylan N.V. announced the combination of the company with Upjohn, a division of Pfizer, the new company formed would be named as Viatris. The merger of both the companies to develop a combined firm has expanded the company’s product portfolio leading to increased demand for its product in the market.

The company has wide presence across North America, Europe, South America, Asia-Pacific, Middle East and Africa. It also has various subsidiary companies including Agila Australasia Pty Ltd (Australia), Alphapharm Pty. Ltd. (Australia), Meda Pharmaceuticals Pty Ltd (Australia), Mylan Australia Holding Pty Ltd (Australia), Mylan Health Pty. Ltd. (Australia), and Arcana Arzneimittel GmbH (Austria) among others.

Fresenius Kabi AG

Fresenius Kabi AG was founded in 1999 and headquartered in Bad Homburg, Germany. The company specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. It has following business segments including Fresenius Medical Care, Fresenius kabi, Fresnius Helios, and Fresnius Vamed in which Fresenius Kabi is the market focused segment. The company also provides various product categories including animal health, biosimilars, colloids, compounding, infusion technology, IV drugs, parenteral nutrition, standard solutions, and transfusion technology, in which the market focused products lie under IV drugs. The company has initiated many strategic initiatives to expand its market.

For instance,

• In April 2021, Fresenius Kabi in Haina was again recognized as Best Place to Work in the Dominican Republic and the Caribbean. The recognition increased the credibility of the company in the market and thus increased its revenue generation.

The company has wide presence across Americas, Europe, Asia-Pacific, Oceania, and Middle East and Africa. It has various subsidiary companies such as HELIOS Kliniken GmbH (Germany), Curalie GmbH (Germany), Else Kröner-Fresenius-Stiftung (Germany), Vamed Management Und Service Gmbh Deutschland (Germany), and Calea Ltd. (Canada) among others.